Brief: Tarsus Pharmaceuticals Q4 Basic EPS USD -0.6
25/02/2025 12:00
Feb 25 (Reuters) - Tarsus Pharmaceuticals Q4 operating expenses USD 90.829 million. * Q4 net income USD -23.113 million vs. IBES estimate USD -29.9 million
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)